Purple Biotech Ltd. (PPBT) has released an update.
Purple Biotech Ltd. has announced promising interim results from a Phase 2 study of its pancreatic cancer treatment, CM24, which will be presented at the ASCO 2024 Annual Meeting. The study shows a reduced risk of disease progression or death when CM24 is used in combination with nivolumab and chemotherapy, compared to chemotherapy alone. Enthusiasm is high as the company looks forward to sharing detailed findings later this year at the prestigious oncology conference.
For further insights into PPBT stock, check out TipRanks’ Stock Analysis page.
